Investor Profile: Inkef — Thesis, Cheque Size & How to Apply

Inkef is one of the Netherlands' largest early-stage venture capital funds — an Amsterdam-based, hands-on investor that backs mission-driven healthcare and technology companies and stays with them for the long haul. For founders comparing startup funding options in Europe's life-sciences and tech corridors, Inkef's patient-capital model (fewer bets, deeper involvement, support across several rounds) is a distinctive route to know.

Thesis: long-term, hands-on capital for mission-driven founders

The firm describes itself as an early-stage, hands-on investor that helps build companies, believing that true value and sustainable returns are created with a long-term strategic vision. Inkef prides itself on being a patient investor: it backs promising early-stage ventures and supports them through several rounds of funding as they grow into international businesses. It focuses on mission-driven entrepreneurs rather than chasing quick exits, emphasising active support, dialogue and performance as core values.

Sectors and stages

Inkef invests in two broad domains. In healthcare it covers biotechnology, therapeutics, diagnostics, digital health and medical devices; in technology it covers enterprise software, IT/new media, fintech, HRTech, cybersecurity and marketplaces. It targets early-stage companies — primarily Seed and Series A, with the capacity to follow on — and invests across Europe, with a strong Benelux base and portfolio companies also in the UK, Germany, Switzerland, the Nordics and the US.

Fund size and cheque size

A 2018 company announcement stated that Inkef had €500 million under management, making it one of the largest venture capital funds in the Netherlands — that figure dates from 2018, and the firm has not published a newer total AUM number. The firm does not publish its cheque size; third-party databases estimate typical tickets in the region of €500k–€15M, so founders should confirm the current range directly with the team before assuming a fit.

Notable portfolio

Inkef has participated in significant rounds across biotech and tech, including co-leading the €80M Series B of Precirix, a clinical-stage biotech developing precision radiopharmaceuticals for oncology; a €20M Series A co-lead for Calypso Biotech, working on treatments for autoimmune diseases; and seed-stage investments in Anavo Therapeutics (seed rounds totalling €28M) and Scenic Biotech. Its technology portfolio has included developer platform GitLab and remote-work platform Remote.

Partners

The investment team is led by Managing Directors Roel Bulthuis, who heads the healthcare practice (previously founder of M Ventures, Merck KGaA's corporate venture fund, and a Kauffman Fellow), and Robert Jan Galema, who heads the technology practice. The healthcare and technology split mirrors the firm's two-pillar strategy.

Programs, credits and perks

Inkef runs no public accelerator programme or standardised credits/perks package. Its value proposition is hands-on, partner-level support: active mentoring, help with strategic decisions, and patient follow-on capital across rounds. Founders engage directly with the investment team rather than through a cohort programme.

How to apply for funding

Inkef does not publish a public application form. The firm lists a public enquiries contact — [email protected] and +31 20 794 6060 — and founders typically approach through the website or a warm introduction to one of the two sector teams (healthcare or technology). Cold outreach should show why the company fits Inkef's long-term, mission-driven mandate.